MAPK1 and acute myeloid leukemia: RAF inhibitors combined with asciminib can treat acute myeloid leukemia (AML) with BCR-ABL-TKI resistance.113 The ERK inhibitor, ulixertinib, combined with dasatinib synergistically expedited NB cell death.114 Furthermore, the combination of MEK inhibitors and TKIs receives the most attention.